On the other hand, the small molecule TK inhibitor GSK1838705A, which inhibits growth of MM cell lines at concentrations below one micromolar, has been reported to inhibit both IGF1 and insulin receptors (in addition to another RTK, anaplastic lymphoma kinase) at comparable IC50 values (2.0 and 1.6 nanomolar, respectively) but elicited only minimal effects on glucose levels in mice [37]. Here, TKT is linked to Miyoshi myopathy.